ATE206407T1 - Verfahren zur herstellung von hiv proteasinhibitoren - Google Patents
Verfahren zur herstellung von hiv proteasinhibitorenInfo
- Publication number
- ATE206407T1 ATE206407T1 AT95908747T AT95908747T ATE206407T1 AT E206407 T1 ATE206407 T1 AT E206407T1 AT 95908747 T AT95908747 T AT 95908747T AT 95908747 T AT95908747 T AT 95908747T AT E206407 T1 ATE206407 T1 AT E206407T1
- Authority
- AT
- Austria
- Prior art keywords
- piperazine
- optically pure
- producing hiv
- derivatives
- enriched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Cephalosporin Compounds (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19291694A | 1994-02-04 | 1994-02-04 | |
PCT/US1995/001232 WO1995021162A1 (en) | 1994-02-04 | 1995-01-30 | Process for making hiv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE206407T1 true ATE206407T1 (de) | 2001-10-15 |
Family
ID=22711555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95908747T ATE206407T1 (de) | 1994-02-04 | 1995-01-30 | Verfahren zur herstellung von hiv proteasinhibitoren |
Country Status (20)
Country | Link |
---|---|
US (1) | US5663341A (de) |
EP (1) | EP0741712B1 (de) |
JP (1) | JPH09508628A (de) |
KR (1) | KR100337579B1 (de) |
AT (1) | ATE206407T1 (de) |
AU (1) | AU691878B2 (de) |
BR (1) | BR9506727A (de) |
CA (1) | CA2180947A1 (de) |
CZ (1) | CZ291774B6 (de) |
DE (1) | DE69523038T2 (de) |
ES (1) | ES2161863T3 (de) |
FI (1) | FI112218B (de) |
HU (1) | HUT76303A (de) |
NZ (1) | NZ279734A (de) |
RO (1) | RO118292B1 (de) |
RU (1) | RU2135482C1 (de) |
SK (1) | SK281861B6 (de) |
TW (1) | TW472047B (de) |
UA (1) | UA46730C2 (de) |
WO (1) | WO1995021162A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL110255A (en) * | 1993-07-16 | 1998-12-06 | Merck & Co Inc | Creation and resolution of 2 tert-butylcarboxamidopiprazine |
US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
KR100389151B1 (ko) * | 1994-04-22 | 2003-10-04 | 고에이 가가쿠 고교 가부시키가이샤 | 광학활성N-tert-부틸-2-피페라진카르복시아미드의제조방법및그라세미화법 |
ATE163642T1 (de) * | 1994-11-04 | 1998-03-15 | Yamakawa Chemical Ind | Verfahren zur herstellung von optisch aktiven piperazinderivaten und zwischenprodukten für ihre herstellung |
ES2181865T3 (es) * | 1995-01-23 | 2003-03-01 | Lonza Ag | Procedimiento para preparar amidas de acido 1,4,5,6, tetrahidro-pirazina-2-carboxilico. |
US5618937A (en) * | 1995-03-15 | 1997-04-08 | Merck & Co., Inc. | Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide |
US5612484A (en) * | 1995-05-18 | 1997-03-18 | Merck & Co., Inc. | Process for making HIV protease inhibitors |
DE19536658C2 (de) * | 1995-09-30 | 1998-02-19 | Degussa | Verfahren zur kontinuierlichen Herstellung von basischen, cyclischen, optisch aktiven alpha-Aminosäuren |
CA2201218C (en) * | 1996-04-23 | 2004-09-28 | Rudolf Fuchs | Process for the preparation of optically active piperazine-2-carboxylic acid derivatives |
ATE429228T1 (de) | 2003-02-14 | 2009-05-15 | Serono Lab | Derivate von piperazine-2-carboxamide |
GB0314260D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB604185A (en) * | 1940-08-08 | 1948-06-30 | Arthur Mandl | Improvements in electric rectifier systems used in power or control systems such as for follow-up systems |
US3692775A (en) * | 1969-03-17 | 1972-09-19 | Allied Chem | Racemization of d-or l-{60 -amino-caprolactam in the presence of metal ions |
US3852351A (en) * | 1972-10-02 | 1974-12-03 | Fmc Corp | Chlorination of acetoacetamides |
JPH01117869A (ja) * | 1987-10-30 | 1989-05-10 | Hokuriku Seiyaku Co Ltd | 2−アミノメチルピペラジン誘導体 |
CA1340588C (en) * | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
CA2195027C (en) * | 1991-11-08 | 2000-01-11 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
MX9308016A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
-
1995
- 1995-01-27 TW TW084100727A patent/TW472047B/zh not_active IP Right Cessation
- 1995-01-30 UA UA96093433A patent/UA46730C2/uk unknown
- 1995-01-30 BR BR9506727A patent/BR9506727A/pt active Search and Examination
- 1995-01-30 ES ES95908747T patent/ES2161863T3/es not_active Expired - Lifetime
- 1995-01-30 RU RU96117468/04A patent/RU2135482C1/ru not_active IP Right Cessation
- 1995-01-30 EP EP95908747A patent/EP0741712B1/de not_active Expired - Lifetime
- 1995-01-30 CA CA002180947A patent/CA2180947A1/en not_active Abandoned
- 1995-01-30 CZ CZ19962272A patent/CZ291774B6/cs not_active IP Right Cessation
- 1995-01-30 HU HU9602143A patent/HUT76303A/hu unknown
- 1995-01-30 RO RO96-01576A patent/RO118292B1/ro unknown
- 1995-01-30 NZ NZ279734A patent/NZ279734A/en unknown
- 1995-01-30 KR KR1019960704219A patent/KR100337579B1/ko not_active IP Right Cessation
- 1995-01-30 SK SK1006-96A patent/SK281861B6/sk unknown
- 1995-01-30 AT AT95908747T patent/ATE206407T1/de not_active IP Right Cessation
- 1995-01-30 JP JP7520686A patent/JPH09508628A/ja not_active Withdrawn
- 1995-01-30 DE DE69523038T patent/DE69523038T2/de not_active Expired - Fee Related
- 1995-01-30 WO PCT/US1995/001232 patent/WO1995021162A1/en active Search and Examination
- 1995-01-30 AU AU16967/95A patent/AU691878B2/en not_active Ceased
- 1995-06-07 US US08/487,903 patent/US5663341A/en not_active Expired - Fee Related
-
1996
- 1996-08-01 FI FI963054A patent/FI112218B/fi active
Also Published As
Publication number | Publication date |
---|---|
CA2180947A1 (en) | 1995-08-10 |
MX9603218A (es) | 1997-07-31 |
NZ279734A (en) | 1998-05-27 |
EP0741712A1 (de) | 1996-11-13 |
RU2135482C1 (ru) | 1999-08-27 |
AU691878B2 (en) | 1998-05-28 |
SK281861B6 (sk) | 2001-08-06 |
AU1696795A (en) | 1995-08-21 |
CZ227296A3 (en) | 1997-01-15 |
FI963054A0 (fi) | 1996-08-01 |
HUT76303A (en) | 1997-07-28 |
HU9602143D0 (en) | 1996-09-30 |
DE69523038T2 (de) | 2002-06-06 |
BR9506727A (pt) | 1997-09-23 |
FI112218B (fi) | 2003-11-14 |
EP0741712B1 (de) | 2001-10-04 |
WO1995021162A1 (en) | 1995-08-10 |
TW472047B (en) | 2002-01-11 |
FI963054A (fi) | 1996-08-01 |
US5663341A (en) | 1997-09-02 |
RO118292B1 (ro) | 2003-04-30 |
JPH09508628A (ja) | 1997-09-02 |
UA46730C2 (uk) | 2002-06-17 |
CZ291774B6 (cs) | 2003-05-14 |
DE69523038D1 (de) | 2001-11-08 |
KR100337579B1 (ko) | 2002-11-13 |
SK100696A3 (en) | 1997-03-05 |
ES2161863T3 (es) | 2001-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69505190T2 (de) | Verfahren zur Herstellung von hochreiner Essigsäure | |
ATE348814T1 (de) | Verfahren zur herstellung von chinolinderivaten | |
ATE206407T1 (de) | Verfahren zur herstellung von hiv proteasinhibitoren | |
DE69403210D1 (de) | Verfahren zur herstellung von n-acetylneuraminsäure | |
DE69426979D1 (de) | Verfahren zur herstellung von hiv-proteasehemmern | |
DE60003846D1 (de) | Verfahren zur herstellung von substituierten pyrazolen | |
ATE233249T1 (de) | Verfahren zur herstellung von hiv protease inhibitoren | |
PT1169326E (pt) | Novo processo para a preparacao de acido alendronico | |
ATE201197T1 (de) | Diarinopropanole abgeleitet von aminosäuren | |
DE60039299D1 (de) | Verfahren zur herstellung von optisch aktiven azetidin-2-carbonsäuren | |
DE60039533D1 (de) | Verbessertes verfahren zur herstellung von 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin | |
DE69819538D1 (de) | Verfahren zur verbesserung der optischen reinheit von 2r-[1-hydroxy-1-trifluormethyl-3-cyclopropylpropyn-2-yl]-4-chloranilin | |
ATE554094T1 (de) | Verfahren zur herstellung von 3-cephem- verbindungen | |
DE69821763D1 (de) | Verfahren zur herstellung von 2-alkylthio-substituierten benzoesäurederivaten | |
ATE193280T1 (de) | Verfahren zur herstellung von beta-amino-alpha- hydroxycarbonsäuren und deren derivaten | |
ATE301637T1 (de) | Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren | |
ATE200776T1 (de) | Verfahren zur herstellung von 2,4,5-tribrompyrrol-3-carbonitril | |
ATE161822T1 (de) | Verfahren zur herstellung von (s)-4-aminohepta- 5,6-diencarbon-säure und intermediate | |
ATE175199T1 (de) | Verfahren zur herstellung von 2-substituierten 5- chlorimidazol-4-carbaldehyden | |
ATE423215T1 (de) | Verfahren zur herstellung von lysosphingolipiden | |
DE69416117T2 (de) | Verfahren zur herstellung von kondensierten carbapenemderivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |